Key Highlights
- DaVita (NYSE:DVA) shares gained 3.54% to USD 161.88 on November 20, 2026.
- The stock slid about 16% over the past month.
- Expanded hemodialysis is now available at every U.S. centre.
- Physicians prescribed it for 95% of eligible patients within two weeks.
A Rebound After a Monthly Slide
DaVita (NYSE:DVA), a leading provider of kidney dialysis services in the United States, gained 3.54% to USD 161.88 on November 20, 2026. No new company announcement appeared on the day. The shares slid about 16% over the past month, which left them well below the 52-week high of USD 247.49 and above the low of USD 101.00. On November 17 the company announced that expanded hemodialysis is now available at every U.S. centre, with physicians prescribing it for 95% of eligible patients within two weeks of the rollout. The therapy works with existing machines. The company gave no financial impact, and clinical outcome benefits are still being evaluated. Dialysis treats patients whose kidneys no longer work, and treatments are needed several times a week, so Revenue is recurring and tied to patient numbers. A large share of patients is covered by government insurance, which sets prices, so the company has limited control over what it earns per treatment.
Healthcare Backdrop and Berkshire Filing
Healthcare names were hit by managed-care weakness that week. UnitedHealth (NYSE:UNH) slid on a senator's push to break up health conglomerates and on CMS's proposed CRUSH rule. Berkshire Hathaway (NYSE:BRK.B) filed a report showing a small trim of about 0.6% in its DaVita stake, which is tied to keeping its holding below 45%, so it is not a vote of no confidence. Argus cut its target to USD 164, close to the current price. UBS has a Street-high target of USD 287. The market Capitalization is USD 10.17 billion, the forward price to Earnings ratio is 10.08, the trailing ratio is 12.69 and trailing diluted EPS is USD 14.11. Argus's lower target sits close to the current share price, which suggests that firm sees limited near-term upside, while UBS's higher number suggests a larger gain is possible. The spread shows how much views differ on the sustainability of margins.
Risks: Cost Pressure and Reimbursement
Supporters argue that the stock trades near 12.8 times forward earnings, against an industry average near 20.6 times, with a PEG Ratio of 0.48. Skeptics argue that after a roughly 40% gain over 52 weeks, views are split, with several Hold ratings, and the monthly slide points to fragile sentiment. Cost pressure, labour expenses and reimbursement rates are the key drivers of profit for a dialysis operator, and treatment Volume growth must offset them. Expanded hemodialysis adoption is rapid, but without disclosed financial impact investors cannot yet judge its effect on margins. Watch treatment volumes, reimbursement updates and any clinical outcome data. A rebound after a month-long decline is not unusual, and traders often buy a stock that has fallen quickly when its valuation looks low. Whether the move lasts depends on quarterly volume trends, which have been the main driver of the stock's earlier gains.
Where Things Stand
DaVita (NYSE:DVA) gained without a new announcement, rebounding after a 16% monthly slide. Rapid adoption of expanded hemodialysis and a low forward multiple support the shares, and Berkshire's small trim is explained by its ownership cap. On the flip side, no financial impact was disclosed, costs are rising and sentiment is fragile. Treatment volumes and reimbursement will decide the next move. A one-day gain after a long decline is a small data point, so investors should watch for steady treatment volume rather than a single session. The stock is US-listed, so this reflects Friday's US session.






Please wait processing your request...